medigraphic.com

2000, Número 3

<< Anterior

Arch Cardiol Mex 2000; 70 (3)


Concentraciones bajas de lipoproteínas de alta densidad (hdl) en plasma y enfermedad arterial coronaria

Pérez-Méndez O, Luc G, Posadas-Romero C

Idioma: Español
Referencias bibliográficas: 62
Paginas: 312-321
Archivo PDF: 285.16 Kb.


FRAGMENTO

Es bien conocido que la concentración plasmática de colesterol-HDL (C-HDL) presenta una correlación negativa con el riesgo de aterosclerosis. De esta manera, es muy probable que la mayor parte de los sujetos con niveles bajos de C-HDL en plasma (hipoalfalipoproteinemia) tengan mayor riesgo de desarrollar enfermedad arterial coronaria (EAC). Sin embargo, existen algunas hipoalfalipoproteinemias que no están asociadas al desarrollo de aterosclerosis. En vista de estas evidencias y dado que no ha sido bien demostrada la relación causal entre hipoalfalipoproteinemia y EAC, se abre la posibilidad de que, en ciertos pacientes, las causas primarias de la enfermedad promuevan adicionalmente niveles bajos de C-HDL en plasma como un epifenómeno. En esos casos, la hipoalfalipoproteinemia no sería factor de riesgo de aterosclerosis, no obstante la presencia simultánea de ambas anomalías. Ésta podría ser una explicación adicional de las observaciones epidemiológicas referentes a la correlación negativa entre C-HDL plasmático e incidencia de EAC.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gordon t, castelli wp, hjortland mc, dawber tr: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.

  2. Miller gj, miller ne: Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-19.

  3. Miller ne: Associations of high-density lipoprotein subclasses and apolipoproteins with ischaemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589-597.

  4. Parra hj, arvelier d, evans ae, cambou jp, amouyel p, bingham a, et al: A case-control study of lipoprotein particles in two populations at constraining risk for coronary heart disease. Arterioscler Thromb 1992; 12: 701-707.

  5. Phillips mc, rothblat gh: HDL and cholesterol efflux. Atherosclerosis 1997; 134: 114.

  6. Williams pt, vranizan km, austin ma, Krauss rm: Association of age, adiposity, alcohol intake, menstrual status and estrogen therapy with high density lipoprotein subclasses. Arterioscler Thromb 1993, 13: 1654-1661.

  7. Castro gr, fielding cj: Early incorporation of cell-derived cholesterol into pre-b-migrating high density lipoprotein pathway. Biochemistry 1988; 27: 25-29.

  8. Koizumi j, mabushi h, takeda r: Deficiency of serum cholestery lester transfer activity in patients with familial hyperalphalipoproteinaemia. Arteriosclerosis 1985; 58: 175-186.

  9. Abbey m, calvert gd: Effects of blocking plasma transfer protein activity in the rabbit. Biochim Biophys Acta 1989; 1003: 20-29.

  10. Tan kc, shiu sw, kung aw: Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998; 83: 2921-2924.

  11. Tan kc, shiu sw, kung aw: Plasma cholesteryl ester transfer protein activity in hyper and hypothyroidism. J Clin Endocrinol Metab 1998; 83: 140-143.

  12. Cushing sd, berliner ja, valente aj, territo mc, navab m, parhami f, et al: Minimally modified low density lipoprotein induces monocyte chemotactic protein (MCP-1) in human endotelial and smooth muscle cells. Proc Natl Acad Sci 1990; 87: 5134-5138.

  13. Seifert ps, kazatchine md: Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol 1987; 24: 1303-1308.

  14. Torzewiski j, oldroyd r, lachman p, fitzimmons c, proudfoot d, bowyer d: Complement-induced release of lesion formation. Arterioscler Thromb Vasc Biol 1996; 16: 673-677.

  15. Watson ad, berliner ja, hama sy, La Du bn, faull kf, fogelman am, et al: Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest 1995; 96: 2882-2891.

  16. Sanghera dk, saha n, aston ce, kamboh y: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-1073.

  17. Aviram m, rosenblat m, bisgaier cl, newton rs, primo-parmo sl, la du b: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101: 1581-1590.

  18. Parthasarathy s, barnett j, fong lg: High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-283.

  19. Abbot na, mackness mi, kumar s, boulton ajm, durrington pn: Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 812-818.

  20. Nevin dn, zambon a, furlong ce, richter rj, humbert r, hokanson je, et al: Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996; 16: 1243-1249.

  21. Shih dm, gu l, hama s, xia yr, navab m, fogelman am, lusis aj: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630-1639.

  22. De Backer g, rosseneu m, deslypere tp: Discriminative value of lipids and apolipoproteins in coronary disease. Atherosclerosis 1982; 42: 197-203.

  23. Franzen j, fex g: Low serum lipoprotein A-I in acute myocardial infraction survivors with normal HDL cholesterol. Atherosclerosis 1986; 59: 37-42.

  24. Rubin em, krauss r, spangler e, verstuyft s, clift s: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353: 265-267.

  25. Hayec t. Oiknine j, danker g, brook jg, aviram m: HDL apolipoprotein A-I attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33: 721-725.

  26. Li h, reddick rl, maeda n: Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-1821.

  27. Huang y, eckardstein a, wu s, maeda n, assmann g: A plasma lipoprotein containing only apolipoprotein E and with mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994; 91: 1834-1838.

  28. Stangl h, cao g, wyne kl, hobbs hh: Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoprotein, low density lipoproteins, and nonlipoprotein cholesterol. J Biol Chem 1998; 273: 31002-31008.

  29. Landschulz kt, pathak rk, rigotti a, krieger m, hobbs hh: Regulation of scavenger receptor, class B. type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98: 984-995.

  30. Rigotti a, edelman er, seifert p, iqbal sn, demattos rb, temel re, et al: Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem 1996; 271: 33545-33549.

  31. Wang n, weng w, breslow jl, tall ar: Scavenger receptor BI (SR-BI) is up-regulate in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J Biol Chem 1996; 271: 21001-21004.

  32. Kwiterovich PO: The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13Q-21Q.

  33. Ahumada am, jimenez vc, cardoso sg, sienra pj, zamora gj, posadas rc: Hypoalphalipoproteinemia and atherosclerosis. Genetic and biochemical profile of 10 families. Arch Inst Cardiol Méx 1989; 59: 9-18.

  34. Borecki ib, laskarzewski p, rao DC: Genetic factors influencing apolipoprotein AI and AII levels in a kindred with premature coronary heart disease. Genet Epidemiol 1988; 5: 393-406.

  35. Borecki ib, rao dc, third jl, laskarzewski pm, glueck cj: A major gene for primary hypoalphalipoproteinemia. Am J Hum Genet 1986; 38: 373-381.

  36. Byard pj, borecki ib, glueck cj, laskarzewski pm, third jl, rao dc: A genetic study of hypoalphalipoproteinemia. Genet Epidemiol 1984; 1: 43-51.

  37. Glueck cj, melser ma, borecki ib, third jl, rao dc, laskarzewski pm: Familial hypoalphalipoproteinemia. Adv Exp Med Biol 1986; 201: 83-92.

  38. Tall A: Plasma lipid transfer proteins. Annu Rev Biochem 1995; 64: 235-257.

  39. Jiang x-c, bruce c, mar j, lin m, ji y, francone ol, et al: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103: 907-914.

  40. Johansson j, nilsson-ehle p, carlson la, hamsten a: The association of lipoprotein and hepatic lipase activities with high density lipoprotein subclass levels in men with myocardial infarction at young age. Atherosclerosis 1991; 86: 111-122.

  41. Serfaty-lacrosniere c, civeira f, lanzberg a, isaia P, berg j, janus ed, et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107: 85-98.

  42. Norum ra, lakier jb, goldstein s, angel a, goldberg rb, block wd, et al: Familial deficiency of apolipoproteins AI and CIII and precocious coronary-artery disease. N Engl J Med 1982; 306: 1513-1519.

  43. Schaefer ej, ordovas jm, law sw, ghiselli g, kashyap ml, srivastava ls, et al: Familial apolipoprotein AI and CIII deficiency, variant II. J Lipid Res 1985; 26: 1089-1101.

  44. Franceschini g, sirtori cr, capurso a, weisgraber kh, mahley RW: A-I Milano Apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66: 892-900.

  45. Bruckert e, von eckardstein a, funke h, beucler i, wiebusch h, turpin g, et al: The replacement of arginine by cysteine at residue 151 in apo A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis 1997; 128: 121-128.

  46. Pérez-méndez o, castro g, fruchart jc, luc g: Kinetic and metabolic studies of apo A-I and apo A-II in an hypoalphalipoproteinemic patient. Eur J Neurology 1995; 2 (Suppl 1): 77.

  47. Elhalil l, majd z, bakir r, pérez-méndez o, castro g, poulain p, et al: Fish eye disease: Structural and in vivo metabolic abnormalities of high density lipoproteins. Metabolism 1997; 46: 474-483.

  48. Rader dj, gregg re, meng ms, schaefer jr, zech la, benson nm, et al: In vivo metabolism of a mutant apolipoprotein, apo A-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 1992; 33: 755-763.

  49. Rader dj, ikewaki k, duverger n, feuerstein i, zech l, connor w, et al: Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993; 342:1455-1458.

  50. Roma p, gregg re, Meng ms, ronan r, zech la, franceschini g, et al: In vivo metabolism of a mutant form of apolipoprotein A-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993; 91: 1445-1452.

  51. Pérez-méndez o, bruckert e, franceschini g, duhal n, lacroix b, bonte jp, et al: Metabolism of apolipoproteins A-I and A-II in subjects carrying similar apo A-I mutations, apo A-I Milano and apo A-I Paris. Atherosclerosis 2000; 148: 317-325.

  52. Schaefer ej, blum cb, levy ri, jenkins ll, alaupovic p, foster dm, et al: Metabolism of high density apolipoproteins in Tangier disease. N Engl J Med 1978; 299: 905-910.

  53. Nichols wc, gregg re, brewer hb, benson MD: Characterization of the gene for familial amyloidotic polyneuropathy (FAP III/Iowa) and genotyping by allele-specific PCR. Am J Hum Genet 1989; 45 (suppl): A210.

  54. Nichols wc, gregg re, brewer hb jr, benson md: A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990; 8: 318-323.

  55. Von eckardstein a, funke h, henke a, altland k, benninghoven a, assmann g, et al: Apolipoprotein A-I variants: naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest 1989; 84: 1722-1730.

  56. Matsunaga t, hiasa y, yanagi h, maeda t, hattori n, yamakawa k, et al: Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gen. Proc Natl Acad Sci 1991; 88: 2793-2797.

  57. Funke h, von eckardstein a, pritchard ph, karas m, albers jj, Assmann G: A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 1991; 87: 371-376.

  58. Rall sc jr, weisgraber kh, mahley rw, ogawa y, Fielding cj, utermann g, et al: Abnormal lecithin: cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J Biol Chem 1984; 259: 10063-10070.

  59. Miller m, aiello d, pritchard h, friel g, zeller k: Apolipoprotein A-I (Zavalla) (Leu159—>Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1242-1247.

  60. Miettinen he, jauhiainen m, gylling h, ehnholm s, palomaki a, miettinen ta, et al: Apolipoprotein A-IFIN (Leu159—>Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 1997; 17: 3021-32.

  61. Strobl w, jabs h-u, hayde m, holzinger t, assmann g, widhalm k: Apolipoprotein A-I (glu198-to-lys): a mutant of the major apolipoprotein of hiph-density lipoproteins occurring in a family with dyslipoproteinemia. Pediatr Res 1988; 24: 222-228.

  62. Ng ds, leiter la, vezina c, connelly pw, hegele ra: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994; 93: 223-229.




2020     |     www.medigraphic.com